NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
5 hedge funds and large institutions have $3.85K invested in NLS Pharmaceutics Warrant in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
1.62% less ownership
Funds ownership: 2.58% → 0.96% (-1.6%)
17% less funds holding
Funds holding: 6 → 5 (-1)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
86% less capital invested
Capital invested by funds: $28.3K → $3.85K (-$24.4K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$106 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$14.3K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$842 |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$368 |
| 4 |
CS
Clear Street
New York
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
Altium Capital Management
New York
| $2.28K | – | – | – |
|
|
2
Hudson Bay Capital Management
Stamford,
Connecticut
| $1.11K | -$842 | -28,644 | -29% |
|
|
3
Citadel Advisors
Miami,
Florida
| $224 | +$106 | +3,618 | +23% |
|
|
AC
4
Armistice Capital
New York
| $143 | -$14.3K | -487,500 | -98% |
|
|
CS
5
Clear Street
New York
| $94 | -$1 | -29 | -0.4% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$368 | -12,221 | Closed |
|
NLSPW Hedge Fund Activity: Q3 2024 in Review
5 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q3 2024, worth a combined $3.85K — down 86% from $28.3K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NLSPW and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, adding an estimated $106. The largest seller was Armistice Capital, cutting an estimated $14.3K.
- 5 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q3 2024, down from 6 in Q2 2024.
- Funds reported $3.85K of NLS Pharmaceutics Warrant stock for Q3 2024, down 86% quarter-over-quarter.
- 0 funds opened new NLS Pharmaceutics Warrant positions in Q3 2024 and 1 closed out, a net change of -1 holder.
- The largest NLS Pharmaceutics Warrant buyer in Q3 2024 was Citadel Advisors, an estimated $106 added.
- The largest NLS Pharmaceutics Warrant seller in Q3 2024 was Armistice Capital, an estimated $14.3K sold.
Based on aggregated 13F filings for Q3 2024.